AMAG Pharmaceuticals Stock News

AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.

AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating restated by analysts at Needham & Company LLC in a research report issued on Monday, AnalystRatings.com reports. Other research a

In a report issued on March 4, Serge Belanger from Needham maintained a Hold rating on Amag Pharmaceuticals (AMAG). The company's shares closed last

In a report issued on March 4, Serge Belanger from Needham maintained a Hold rating on Amag Pharmaceuticals ( AMAG – Research Report ). The company’s shares closed last Monday at $7.68, close to i

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities research analysts at Jefferies Financial Group boosted their FY2021 EPS estimates for AMAG Pharmaceuticals in a research note issued on Wednesday,

Barclays analyst Balaji Prasad maintained a Buy rating on Amag Pharmaceuticals (AMAG) on March 6 and set a price target of $11.00. The company's shares

Barclays analyst Balaji Prasad maintained a Buy rating on Amag Pharmaceuticals ( AMAG – Research Report ) on March 6 and set a price target of $11.00 . The company’s shares closed last Monday at $

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

AMAG Pharmaceuticals (NASDAQ:AMAG) had its target price reduced by HC Wainwright from $16.00 to $12.00 in a report published on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on th

Last month, Gilead Sciences CEO Daniel O’Day announced plans to introduce 10 “transformative medicines” over the next 10 years. Acquisitions would help

As you might know, AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) recently reported its annual numbers. It looks like the...

AMAG Pharmaceuticals (NASDAQ:AMAG) had its target price lowered by investment analysts at Piper Sandler from to in a report issued on Thursday, The Fly reports. Several other equities analysts also re

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

AMAG Pharmaceuticals is losing its CEO, likely having a drug pulled off the market by the FDA and has cut more than 100 staffers; as it turns more deeply to its pipeline, the person in charge of that